Share

September 2019; 6 (5) ArticleOpen Access

Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes

Ari Breiner, Carolina Barnett Tapia, Leif Erik Lovblom, Bruce A. Perkins, Hans D. Katzberg, Vera Bril
First published July 10, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000586
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1298

Share

Article Information

vol. 6 no. 5 e586
DOI: 
https://doi.org/10.1212/NXI.0000000000000586
PubMed: 
31454771
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received February 13, 2019
  • Accepted in final form May 28, 2019
  • First Published July 10, 2019.
Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Ari Breiner, MD, MSc, FRCPC,
    2. Carolina Barnett Tapia, MD, PhD,
    3. Leif Erik Lovblom, MSc,
    4. Bruce A. Perkins, MD, MPH, FRCPC,
    5. Hans D. Katzberg, MD, MSc, FRCPC and
    6. Vera Bril, MD, FRCPC
  1. Ari Breiner, MD, MSc, FRCPC,
    2. Scientific Advisory Boards:

    1. (1) Pfizer (2) Akcea

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) CSL Behring (2) Allergan

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Grifols, Inc.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) GBS-CIDP International Foundation (2) Muscular Dystrophy Canada

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Carolina Barnett Tapia, MD, PhD,
    3. Scientific Advisory Boards:

    1. Canadian Advisory board for Alexion

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Alexion (2)Akcea (3) Grifols (4) Takeda

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Research grant from Octapharma, for clinician-initiated research (2) research grant from Grfiols for clinician-initiated research

    Research Support, Government Entities:

    1. (1) US Department of Defense. Neurofibromatosis program, new investigator award. Role: PI, year: 2019-2022 (2) NIH. PAR-17-184. Role: Co-investigator. 2018-2023

    Research Support, Academic Entities:

    1. (1) New initiatives grant. University of Toronto, Division of Neurology

    Research Support, Foundations and Societies:

    1. (1) Muscular Dystrophy Canada. Seed Grant. Role; co-investigator. 2019-2020

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) May receive future royalties for licensing of the MGII

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Leif Erik Lovblom, MSc,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Bruce A. Perkins, MD, MPH, FRCPC,
    5. Scientific Advisory Boards:

    1. 1. Advisor for Boehringer Ingelheim (Commercial entity) 2. Advisor for Abbott (Comercial Entity)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Honoraria for continuing medical education events from Abbott (Commercial entity), Medtronic (Commercial entity), Boehringer Ingelheim (Commercial entity), Janssen (Commercial entity), Insulet (Commercial entity), Janssen (Commercial entity)

    Editorial Boards:

    1. Diabetes Care, Editorial board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Operating funds were paid to my research institution by Boehringer Ingelheim (Commercial entity) and Bank of Montreal (Commercial Entity) for work that I am the local principal investigator on.

    Research Support, Government Entities:

    1. 1) NIH/NIDDK 2) Canadian Institutes for Health Research

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) JDRF 2) Diabetes Canada

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Hans D. Katzberg, MD, MSc, FRCPC and
    6. Scientific Advisory Boards:

    1. Data safety monitoring board for Octapharma clinical study.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) Genzyme Canada - funding for air, hotel to Steps Forward Meeting Berlin, Germany ∼4K 2) Speaker honoraria from CSL Behring, Grifols, Genzyme, Akcea, Terumo

    Editorial Boards:

    1. Associate Editor CJNS 2014-2019.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) CSL Behring - investigator initiated grant on SCIG for MMN

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. 1) University of Toronto Division of neurology - New Initiative Grant for assessment of sleep in MG

    Research Support, Foundations and Societies:

    1. 1) Myasthenia Gravis Foundation of America - research grant on PET labeling for MG

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Vera Bril, MD, FRCPC
    7. Scientific Advisory Boards:

    1. (1) CSL Behring (2) Argenyx (3) UCB

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) CSL Behring

    Editorial Boards:

    1. (1) PLoS One, editorial board member starting 2016

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Alnylam (2) Alexion (3) Akcea (4) Pfizer (5) CSL Behring (6) Grifols (7) Octapharma (8) Powell Mansfield Inc, (9) Argenyx (10) UCB (11) Immunovant (12) Takeda (Shire)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) CSL Behring (2) Baxalta (3) Grifols (4) Argenyx (5) Octapharma (6) Takeda (Shire) (7) UCB

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Toronto General/Toronto Western Hospital Foundation (2) GBS/CIDP Foundation International

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Division of Neurology (A.B.), Department of Medicine, the Ottawa Hospital; Ottawa Hospital Research Institute (A.B.); Division of Neurology (C.B., H.D.K., V.B.), Department of Medicine, Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto; Division of Endocrinology and Metabolism (L.E.L., B.A.P.), Department of Medicine, Mount Sinai, Hospital and Lunenfeld Tanenbaum Research Institute, University of Toronto, Canada; and Institute for Research and Medical Consultations (V.B.), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  1. Correspondence
    Dr. Breiner abreiner{at}toh.ca
View Full Text

Article usage

Article usage: July 2019 to May 2023

AbstractFullPdfSource
Jul 201924925274Highwire
Aug 20191337656Highwire
Sep 2019243449106Highwire
Oct 20194182492Highwire
Nov 20191168084Highwire
Dec 20191041857Highwire
Jan 202038628Highwire
Feb 2020711222Highwire
Mar 202039114Highwire
Apr 202068621Highwire
May 202045223Highwire
Jun 202033323Highwire
Jul 202084922Highwire
Aug 202054013Highwire
Sep 202056030Highwire
Oct 202075835Highwire
Nov 202015339Highwire
Dec 202025829Highwire
Jan 202156023Highwire
Feb 202114025Highwire
Mar 202114531Highwire
Apr 202113526Highwire
May 202124819Highwire
Jun 202123810Highwire
Jul 202123529Highwire
Aug 202164546Highwire
Sep 202114427Highwire
Oct 202134744Highwire
Nov 202104821Highwire
Dec 202123914Highwire
Jan 202205210Highwire
Feb 20222214Highwire
Mar 202214015Highwire
Apr 202223413Highwire
May 20221238Highwire
Jun 202235611Highwire
Jul 202225411Highwire
Aug 20227559Highwire
Sep 202255216Highwire
Oct 202223612Highwire
Nov 202276624Highwire
Dec 202243110Highwire
Jan 202344712Highwire
Feb 202323810Highwire
Mar 202333814Highwire
Apr 202343015Highwire
May 202314421Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles